EntreMed Inc (NASDAQ:ENMD)

Data as of Apr 17
 -0.05 / -2.60%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

EntreMed, Inc. is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. Its drug candidate, ENMD 2076, which is an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. The company was founded in 1991 and is headquartered in Rockville, MD.

Contact Information

EntreMed, Inc.
9620 Medical Center Drive
Rockville Maryland 20850
P:(240) 864-2600
Investor Relations:
(240) 864-2643



Individual stakeholders5.06%
Other institutional10.64%
Mutual fund holders1.73%

Top Executives

Ken Keyong RenChief Executive Officer
Cynthia Wong HuCOO, Secretary, Vice President & General Counsel
Sara B. CapitelliChief Accounting Officer & Vice President-Finance
William E. GannonVice President-Medical & Regulatory Affairs
Ginny DunnDirector-Communications & Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.